Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.71 |
| ▸ | GAA | P10253 | 6/20 | 0.71 |
| ▸ | HTT | P42858 | 5/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | S100B | P04271 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110600 | 0.85 | ALDH1A1 (0.96) | ALDH1A1GAAHTTL3MBTL1MAPT | |
| SCHEMBL3485151 | 0.85 | ALDH1A1 (0.96) | ALDH1A1GAAHTTL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL23043584 | 0.83 | ALDH1A1 (1.00) | ALDH1A1GAAHTTL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL29979151 | 0.83 | ALDH1A1 (1.00) | ALDH1A1GAAHTTL3MBTL1MAPT | |
| SCHEMBL1136241 | 0.82 | ALDH1A1 (0.93) | ALDH1A1GAAHTTL3MBTL1MAPT | |
| SCHEMBL29937765 | 0.82 | ALDH1A1 (0.93) | ALDH1A1GAAHTTL3MBTL1MAPT | |
| SCHEMBL18861760 | 0.81 | ALDH1A1 (0.75) | ALDH1A1GAAHTTL3MBTL1MAPT | |
| SCHEMBL6100179 | 0.81 | LGMN (0.67) | ALDH1A1GAAHTTL3MBTL1MAPT | |
| SCHEMBL28147210 | 0.80 | GAA (0.69) | ALDH1A1GAAHTTL3MBTL1MAPT | |
| SCHEMBL5715880 | 0.80 | ALDH1A1 (0.59) | ALDH1A1GAAHTTMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | claimed |
| EP-1631560-A2 | C-FMS KINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-03-08 | — | — | EP | claimed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | claimed |
| WO-2004096795-A2 | C-FMS KINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | claimed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | ALDH1A1 4731/4885GAA 4492/4885HTT 2335/4885 |
| US-20050004112-A1 | C-fms kinase inhibitors | FLT3, FGR, FER | ALDH1A1 4574/4885GAA 4304/4885HTT 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.